Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Yahoo22 saat önceCOO
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
Yahoo22 saat önceCOO
Countdown to The Cooper Companies (COO) Q3 Earnings: Wall Street Forecasts for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for The Cooper Companies (COO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.
YahoodünCOO
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
YahoodünCOO
Cooper Companies: Cash Conversion And Strategic Optionality Create A Re-Rating Setup
Cooper Companies (COO) outlook: premium lens growth, margin gains, stronger cash flow & possible CooperSurgical sale. Click here to read my latest analysis.
SeekingAlpha3 gün önceCOO
OSTROM CLIMATE REPORTS FISCAL Q2 2026 FINANCIAL STATEMENTS
Ostrom Climate Solutions Inc. ("Ostrom" or the "Company") (TSXV: COO) (Frankfurt: 9EAA), a leading provider of carbon project development, net-zero climate solutions, and carbon credit marketing and trading, today announced its unaudited financial results for the second quarter ended June 30, 2026.
Yahoo6 gün önceCOO
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
Yahoo6 gün önceCOO
1 Mid-Cap Stock with Impressive Fundamentals and 2 Facing Challenges
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Yahoo7 gün önceCOO
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Yahoo13 gün önceCOO
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.
Yahoo13 gün önceCOO
COO vs. MMSI: Which Stock Is the Better Value Option?
COO vs. MMSI: Which Stock Is the Better Value Option?
Yahoo13 gün önceCOO
INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?
Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.
Yahoo13 gün önceCOO
BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?
BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.
Yahoo13 gün önceCOO
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Yahoo14 gün önceCOO
Is Cooper Companies (COO) Cheap After Slower Growth Forecasts Raised Valuation Concerns?
Analyst projections of slower revenue growth for Cooper Companies (COO), along with past growth projects that did not clear the healthcare sector’s cost of capital, have put the stock’s recent underperformance in sharper focus for investors. See our latest analysis for Cooper Companies. Over the past year Cooper Companies has seen some recovery in its share price, with a 90 day share price return of 21.76% and a 1 year total shareholder return of 1.25%. However, the 3 year and 5 year total...
Yahoo14 gün önceCOO
Softening Growth And Subpar Returns On Investment Could Be A Game Changer For Cooper (COO)
In recent months, CooperCompanies has faced a softer outlook as analysts now expect its revenue to grow more slowly than in prior years, pointing to potential demand challenges. An important underlying issue is that past growth investments have generated returns below the healthcare industry’s cost of capital, raising fresh questions about how efficiently management is deploying capital. Next, we’ll examine how this weaker revenue growth outlook and capital efficiency concern could reshape...
Yahoo14 gün önceCOO
Jana Partners Buys Stake in Data Center Stock Everpure, May Be Up Almost 100% Already
Jana Partners adds Everpure stock, a growing player in AI and data center market, to its portfolio. It also lowers its stake in other companies.
Benzinga17 gün önceCOO
HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates
HeartFlow (HTFL) delivered earnings and revenue surprises of +50.00% and +12.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo21 gün önceCOO
Citigroup Maintains Neutral on Cooper Companies, Raises Price Target to $80
Citigroup analyst Joanne Wuensch maintains Cooper Companies (NASDAQ:COO) with a Neutral and raises the price target from $76 to $80.
Benzinga21 gün önceCOO
Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now
Cooper Companies' premium lens migration, MiSight growth and fertility recovery offer long-term upside despite Asia-Pacific, tariff and FX pressures.
Yahoo22 gün önceCOO
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of +47.62% and +3.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo22 gün önceCOO
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
Yahoo23 gün önceCOO
CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.
Yahoo23 gün önceCOO
Cardinal Health (CAH) Q4 Earnings Beat Estimates
Cardinal (CAH) delivered earnings and revenue surprises of +20.25% and -2.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo24 gün önceCOO
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Yahoo24 gün önceCOO